Sponsors & Partners

MaRS HealthKick 2015 thanks its sponsors and partners

Presenting Sponsor

Johnson & Johnson Innovation | JLabs

Award Sponsors

AMGEN AstraZeneca Baxter

Medtronic Saint Elizabeth

Event Partners

Bayshore Healthcare blue line BIOSCIENCE Boehringer Ingelheim CIMTEC

FLEISHMANHILLARD Foreign Affairs, Trade and Development Canada Affaires étrangères, Commerce et Développement Canada

HTX INVENT INNOVATE INVOICE Life Labs Medical Laboratory Services McKesson Canada McKesson Ventures

Miller Thomson Norton Rose Fulbright Ontario Genomics Institute

Roche Sanofi Pasteur TELUS HEALTH

revera

Partners

CVCA Greater Toronto Funding Portal

RBC Royal Bank Ontario Bioscience

Airline Partner

porter
### Pitch Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>BIOTECHNOLOGY &amp; PHARMACEUTICALS – Auditorium A</th>
<th>MEDICAL DEVICES &amp; DIAGNOSTICS – Auditorium B/C</th>
<th>HEALTH IT – Phase 2 Atrium, Multi-Purpose Room</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pitch Showcase Round 1 – 11:15-12:30</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 11:15-11:30</td>
<td>Atomwise</td>
<td>NP Screen</td>
<td>Cogniciti</td>
</tr>
<tr>
<td>2 11:30-11:45</td>
<td>Cyclica</td>
<td>Lumasonix</td>
<td>Merge3D</td>
</tr>
<tr>
<td>3 11:45-12:00</td>
<td>Aereus Technologies</td>
<td>illumiSonics</td>
<td>Alaunus</td>
</tr>
<tr>
<td>4 12:00-12:15</td>
<td>Mirexus Biomedical</td>
<td>VieLight</td>
<td>iamsick.ca</td>
</tr>
<tr>
<td>5 12:15-12:30</td>
<td>Windsor Botanical Therapeutics</td>
<td>MolecuLight</td>
<td>Koronis</td>
</tr>
<tr>
<td><strong>LUNCH – 12:30-1:15</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pitch Showcase Round 2 – 1:15-2:45</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 1:15-1:30</td>
<td>EMERpharma</td>
<td>Medella Health</td>
<td>SeamlessMD</td>
</tr>
<tr>
<td>2 1:30-1:45</td>
<td>Oxalys Pharmaceuticals</td>
<td>VitalSines</td>
<td>Evolution Health Systems</td>
</tr>
<tr>
<td>3 1:45-2:00</td>
<td>Induce Biologics</td>
<td>Aegis Medical Innovations</td>
<td>AprilAge</td>
</tr>
<tr>
<td>4 2:00-2:15</td>
<td>TrendyMED</td>
<td>NerveVision</td>
<td></td>
</tr>
<tr>
<td>5 2:15-2:30</td>
<td>RNA Diagnostics</td>
<td>Shift Health</td>
<td></td>
</tr>
<tr>
<td>6 2:30-2:45</td>
<td>Mindful Scientific</td>
<td>ManagingLife</td>
<td></td>
</tr>
<tr>
<td><strong>COFFEE BREAK – 2:45-3:00</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pitch Showcase Round 3 – 3:00-4:15</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 3:00-3:15</td>
<td>Infonaut</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 3:15-3:30</td>
<td>Proteocyte Diagnostics</td>
<td>GeneYouIn</td>
<td></td>
</tr>
<tr>
<td>3 3:30-3:45</td>
<td>Perimeter Medical Imaging</td>
<td>AceAge</td>
<td></td>
</tr>
<tr>
<td>4 3:45-4:00</td>
<td>Interface Biologics</td>
<td>MEMOTEXT</td>
<td></td>
</tr>
<tr>
<td>5 4:00-4:15</td>
<td>Colibri Technologies</td>
<td>QoC Health</td>
<td></td>
</tr>
</tbody>
</table>

*Following the final pitch, please proceed to the Auditorium for the Reception & Awards.*
Welcome to MaRS HealthKick 2015

MaRS is thrilled to present this year's companies selected for MaRS HealthKick 2015, Canada's largest health venture showcase.

MaRS HealthKick 2015 provides an unparalleled opportunity for Canada's most promising and innovative young, high-growth health startups to get their businesses in front of leading investors and industry partners.

Building on the success of last year's inaugural event, the ventures featured in the 2015 HealthKick DealBook are catalyzing the future of health and healthcare, from advanced drug discovery platforms to novel diagnostic devices and health monitoring tools that empower patients to take control of their own health.

The largest urban innovation centre in the world, MaRS actively supports ambitious and committed entrepreneurs and their high-impact ventures, and works with partners to make our health system more receptive to innovative new products and services. Connecting these high-impact companies with investors and partners is crucial, so they can raise the needed growth capital to scale not only in Canada but also globally.

We encourage you to learn more about the ventures that interest you.

Follow @MaRSDD on Twitter and use the event hashtag #HealthKick2015

Sincerely,
MaRS Health
About MaRS Discovery District

MaRS Discovery District in Toronto is one of the world’s largest urban innovation hubs. MaRS cultivates high-impact ventures and equips innovators to drive economic and societal prosperity. MaRS provides expert advice and market research, and makes connections to talent, customers and capital. MaRS startup ventures have created 6,500 jobs and, in the last three years alone, they have raised $1 billion in capital and generated $500 million in revenue.

About MaRS Health

MaRS Health helps emerging companies create successful global businesses across the full spectrum of industry clusters, including biotechnology and pharmaceuticals, medical devices and diagnostics, health IT, and more. We cultivate a growing network of business mentors, investors and global partners, identify key financing opportunities, and create industry events that help ventures succeed. With an unmatched, curated portfolio of over 300 health startups across Ontario, MaRS Health ventures have raised $172 million in capital, generated $25 million in revenue and created 1,600 jobs in 2013 alone.

Learn more at marsdd.com/health
Table of contents

● Biotechnology and Pharmaceuticals ......................... 10
  Aereus Technologies ........................................... 10
  Atomwise ......................................................... 10
  Cyclica ........................................................ 11
  EMERpharma ....................................................... 11
  Induce Biologics ................................................. 12
  Mirexus Biomedical ............................................ 12
  Oxalys Pharmaceuticals ....................................... 13
  Windsor Botanical Therapeutics ................................ 13

● Health IT .......................................................... 14
  AceAge ............................................................ 14
  Alaunus ........................................................... 14
  AprilAge .......................................................... 15
  Cogniciti .......................................................... 15
  Evolution Health Systems ..................................... 16
  GeneYouIn ......................................................... 16
  iamsick.ca ......................................................... 17
  Infonaut .......................................................... 17
  Koronis ........................................................... 18
  ManagingLife ..................................................... 18
  MEMOTEXT ........................................................ 19
  Merge3D ........................................................... 19
  NerveVision ....................................................... 20
  QoC Health ......................................................... 20
  SeamlessMD ...................................................... 21
  Shift Heath ......................................................... 21
- Medical Devices and Diagnostics
  Aegis Medical Innovations ........................................ 22
  Colibri Technologies ............................................... 22
  illumiSonic.......................................................... 23
  Interface Biologics ................................................ 23
  Lumasonix ........................................................... 24
  Medella Health ...................................................... 24
  Mindful Scientific .................................................. 25
  MolecuLight ........................................................ 25
  NP Screen ............................................................ 26
  Perimeter Medical Imaging ......................................... 26
  Proteocyte Diagnostics ............................................. 27
  Rna Diagnostics ..................................................... 27
  TrendyMED ........................................................ 28
  VieLight .............................................................. 28
  VitalSines .......................................................... 29
Providing a big company platform for emerging healthcare companies

JLABS, part of Johnson & Johnson Innovation LLC, provides the tools and resources needed to help life science startups thrive. Companies have access to turnkey, state-of-the-art infrastructure, onsite team for operations and business services, all with no-strings attached.

Our capital-efficient and flexible platform provides early-stage companies with many of the advantages of being at a big company while preserving an entrepreneur’s equity and freedom to drive his or her technology forward. JLABS’ professional operational management and programming resources free up time for entrepreneurs to build value through pipeline development instead of being sidetracked by getting their businesses up and running.

JLABS produces year-round commercialization curriculum and networking events across North America for the broader life science community. Additionally, JLABS links entrepreneurs with the full breadth of Johnson & Johnson Innovation (www.jnjinnovation.com), including opportunities to discuss funding, access third-party services, attend educational events and meet with R&D experts from our medical device technology, consumer healthcare product and Janssen pharmaceutical teams.

Johnson & Johnson Innovation includes local deal-making capabilities with the flexibility to adapt deal structures to match early-stage opportunities and establish novel collaborations that speed development of innovations to solve unmet needs in patients.

For more information on JLABS, please visit JLABS.jnjinnovation.com
Norton Rose Fulbright is a global law practice with offices in six continents. In Canada, we have more than 600 lawyers and patent and trademark agents throughout Calgary, Montreal, Ottawa, Quebec City and Toronto.

We are known for our industry focus. In Life Sciences and Healthcare, we represent startups, up-and-comers, multinational companies, private equity firms, angel investors and institutional investors. We understand how life sciences companies are formed, financed, operated, grown and commercialized (including public exits or mergers). We work with our clients to establish effective intellectual property strategies, and we provide practical recommendations and direction at all business stages, from initial seed funding through to later financing rounds.

We are an active partner in the innovation process, connecting clients to facilitate commercialization and investment. In the 2014 LMG Life Sciences Awards we were named the Canadian Life Cycle Firm of the Year.

HTX is a proud sponsor of MaRS HealthKick 2015.

REACH Highlights:

- 3.5-year healthcare provider-driven innovation procurement fund
- Supporting provider/innovator partnerships focused on high-priority health system problems
- Targeting late pre-market, early post-market, pre-diffusion technologies where “procurement” and local evidence are challenges
- Matching grant subsidies from $300,000 to $1M for each of 10-12 projects
- Connects Ontario projects to foreign markets through HTX partners

“REACH will help transition the health system towards outcome-based specifications, earlier dialogue with innovative suppliers, and evidence-based adoption.”
- John Soloninka, President/CEO HTX

“An outstanding example of collaboration between the health system, government and industry that aligns perfectly with the recent OHIC recommendations”
- Dr. Dave Williams, Chair OHIC

Visit our booth at MaRS HealthKick 2015 for more details.
Keynote Speakers

This year’s keynote speakers will focus on Patient Empowerment, exploring how innovative health technologies empower patients to become the CEOs of their own health.

**e-Patient Dave**

Dave deBronkart, also known as e-Patient Dave, is the author of Let Patients Help!: A Patient Engagement Handbook and one of the world's leading advocates for patient engagement. After beating Stage 4 kidney cancer in 2007, Dave became a blogger, health policy advisor and international keynote speaker. He is the best-known spokesman for the patient engagement movement, having attended nearly 300 conferences and policy meetings internationally, including testifying in Washington for patient access to medical records under the US Centers for Medicare and Medicaid Services’ policy on meaningful use. Dave is a co-founder of the Society for Participatory Medicine and is currently co-chair of its board of directors. His writings have been published in the British Medical Journal, the Society for General Internal Medicine Forum and iHealthBeat, as well as in the conference journal of the American Society of Clinical Oncology.

**Lucien Engelen**

Lucien Engelen is a global thought leader from Radboud University Nijmegen Medical Centre in the Netherlands who speaks regularly on patient engagement and the role of health technologies. He considers it his personal mission to change healthcare into an environment with a stronger patient perspective through the use of technology.
Melinda Richter

As head of JLABS, Melinda Richter fosters Johnson and Johnson’s external research-and-development engine and supports the innovation community by creating capital-efficient commercialization models that give early-stage companies a big company advantage. Before joining JLABS, she was the CEO of Prescience International, an award-winning firm dedicated to accelerating the amount of time it takes for medical research to reach patients, which she founded after she experienced a medical emergency that left her questioning the efficiency and efficacy of the healthcare system.

Melinda previously held posts across a variety of functional areas within Nortel Networks, in locations including Research Triangle Park, New York City, Toronto, London, Hong Kong and Beijing. She also started, raised capital and orchestrated large corporate deals for several companies in the life science and technology spaces. Melinda holds a bachelor of commerce from the University of Saskatchewan and a master of business administration from INSEAD in France.

Dr. Mike Evans

Dr. Mike Evans is known worldwide for his work in innovative health messaging for the public. More than 10 million people have seen his famous whiteboard lectures on YouTube, and his radio show on CBC’s “Fresh Air” is listened to widely. He and his creative group have pioneered peer-to-peer healthcare through unscripted interviews of patients with cancer in his “Truth of It” video series, health infographics and health media curation, as well as by founding a medical school for the public at the University of Toronto.

Mike is a staff physician at St. Michael’s Hospital in Toronto, an associate professor in the Department of Family and Community Medicine at U of T and a scientist at the Li Ka Shing Knowledge Institute. In 2014, he was appointed the inaugural chair in patient engagement in child nutrition at U of T.
Leslee Thompson

Leslee Thompson is one of Canada’s most influential and respected healthcare leaders. Her unique background includes a combination of clinical, academic, board and executive leadership in top-tier academic centres, retail and medical technology companies, research institutes, government agencies and charities.

Leslee was appointed president and CEO of Kingston General Hospital in February 2009 and has led its transformation from a hospital under government supervision to a high-performing, patient-focused organization. Prior to this role, Leslee was the vice-president of health system strategies at Medtronic Canada. She also previously held senior executive positions at Capital Health Authority in Alberta, University Health Network, Sunnybrook Health Sciences Centre and Cancer Care Ontario. Named one of Canada’s top 100 most powerful women in 2013 by the Women’s Executive Network, Leslee is also an adjunct assistant professor in the Department of Public Health Sciences at Queen’s University.
2015 Juries

BIOTECHNOLOGY & PHARMACEUTICALS JURY

MODERATOR
Chelsea Hewitt
Head of Marketing
Johnson & Johnson Innovation, JLABS

Ian Foltz
Scientific Director
Amgen

Dr. Raphael Hofstein
President & CEO
MaRS Innovation

Dr. Stefan Larson
Entrepreneur-in-Residence
Versant Ventures

Dr. Ron Laufer
Senior Managing Director
MedImmune Ventures

Melinda Richter
Head
Johnson & Johnson Innovation, JLABS
MEDICAL DEVICES & DIAGNOSTICS JURY

**MODERATOR**
David Simmonds  
Vice President, Public Affairs  
McKesson Canada

**Damian Lamb**  
Managing Director  
Genesys Capital

**Michelle McBane**  
Investment Director  
MaRS Investment Accelerator Fund

**Hamid Sadri**  
Director, Health Economics and HTA  
Medtronic

**John Soloninka**  
President & CEO  
HTX

**Dr. Shafiq Qaadri**  
Medical Journalist
HEALTH IT JURY

MODERATOR
Anthony de Fazekas
Partner, Lawyer, Patent Agent
Norton Rose Fulbright Canada

Aaron Flink
Investment Manager
McKesson Ventures

Lesley Larsen
Innovation Seeker
Saint Elizabeth

Kasra Moozar
Vice-President, Corporate Development and International Sales
Telus Health

Richard Osborn
Managing Partner
RecapHealth Ventures

Robert Stewart
Partner
Miller Thomson
Aereus Technologies

www.aereustech.com

Aereus Technologies provides antimicrobial copper-alloy coating services and turnkey installations. Branded as Aereus Shield, our patented process mechanically bonds our alloy to almost any hard surface. Aereus Shield is a permanent, non-tarnishing, self-sanitizing antimicrobial coating. Other benefits include the ability to kill mould, mildew and fungus, and increased moisture and fire resistance. In Canada, Aereus Shield coated Class I and II medical devices can be marketed as antimicrobial within the Medical Devices Regulations (Food and Drugs Act, 1985).

**Seeking:** $7M equity investment, industry partnership/licensing opportunity

**Contact information:**
Michelle Berelowitz, CEO | michelle@aereustech.com

---

Atomwise

www.atomwise.com

Atomwise (previously Chematria) leverages machine learning and big data to rapidly discover new molecules, which it then licenses. Specifically, we apply deep neural networks to predict small-molecule binding affinities. Our technology can be used throughout the drug discovery pipeline from hit discovery and lead optimization, to off-target toxicity identification, mechanism of action elucidation and personalized medicine. We produce results 150x faster than wet lab experimentation and 18x more accurately than existing software.

**Seeking:** Equity investment, industry partnership

**Contact information:**
Abraham Heifets, CEO | abe@atomwise.com
Cyclica

Through its proprietary technology, Ligand Express™, Cyclica identifies interactions between drug candidates and all known proteins. Cyclica’s proprietary databases combined with docking algorithms identify the best configuration for drug-protein interactions, which reveal with high confidence on-target and off-target protein binding. The Ligand Express™ technology is an effective platform that facilitates the drug discovery and optimizing processes for developing safer and efficacious drugs.

Seeking: $5M equity investment, industry partnership/licensing opportunity, customer engagement

Contact information:
Naheed Kurji, CFO | naheed.kurji@cyclicarx.com

EMERpharma

EMERpharma Ltd. is a startup drug development company focused on the development of efficacious, non-addictive treatment for ADHD and treatment for addiction disorders. EMER’s lead compound, EM902, is the only selective inhibitor of BEC1/KCNH3 potassium channels. EM902 was in-licensed from Astellas pharma, has attracted government funding to explore its anti-abuse properties and has worldwide IP protection. Phase 1 clinical testing has been completed and both preclinical and clinical data support a robust efficacy and safety profile.

Seeking: $4.5M equity investment, industry partnership/licensing opportunity

Contact information:
Aldemar Degroot, CEO | a.degroot@emerpharma.com
Induce Biologics
www.inducebiologics.com

Induce Biologics is developing a game-changing product for the multi-billion dollar bone regeneration market, utilizing patented multi-phasic delivery technology to slowly release bone morphogenetic protein (BMP), which attracts the body’s own stem cells and transforms them into bone making cells, stimulating bone regeneration. Preclinical studies demonstrate this unique product produces twice as much bone with half the BMP than currently approved implants. First-in-human clinical trials are planned for 2016.

Seeking: $3M equity investment, strategic partners

Contact information:
Dr. Cameron Clokie, CEO | c.clokie@inducebiologics.com

Mirexus Biomedical
www.mirexus.com

Mirexus Biomedical is commercializing a natural nanotechnology platform for use in the biomedical industry. The technology is built on monodisperse nanophytoglycogen and is geared to produce a wide range of biopharmaceutical products, drug delivery systems, stabilizers for protein drugs and vaccines, and diagnostic systems. This safe and natural product is conveniently modified to provide access to new APIs, and more effective and safe delivery vehicles. The company will commercialize its drugs in international markets in partnership with pharmaceutical companies.

Seeking: $500K equity investment, industry partnership/licensing opportunity

Contact information:
Dr. Phil Whiting, CEO | pwhiting@mirexus.com
Oxalys Pharmaceuticals

Oxalys Pharmaceuticals is developing small molecule therapeutics to slow, halt or reverse the course of neurodegenerative disease. The company's proprietary drug discovery technology targets the causal factors of brain atrophy in neurodegeneration and identified OXD4, which is the company’s lead therapeutic. OXD4 is a broadly neuroprotective molecule, and Oxalys has IP for its use in multiple neurodegenerative diseases with multi-billion markets. As a disease-modifier, it will be superior to current symptomatic dementia therapies that cannot slow disease progression. In 2014, the FDA granted Oxalys orphan drug designation of OXD4 for its use as a treatment of Huntington's disease. The company has since assembled a team of internationally renowned Huntington's disease researchers and neurologists to establish clinical proof-of-concept in a Phase I/II trial.

Seeking: $4M equity investment, industry partnership/licensing opportunity

Contact information:
Katharine Sepp, CEO | ksepp@oxalyspharma.com

Windsor Botanical Therapeutics

Windsor Botanical Therapeutics Inc. (WBTI) is developing DRE-W, a revolutionary natural health product (NHP) for terminal cancer patients refractory to conventional cancer therapy. DRE-W is a patent-pending, non-toxic plant extract. The anecdotal clinical experience and the scientific data were so compelling; Health Canada has approved a clinical trial of DRE-W in patients with terminal hematological cancers. This is the first ever cancer trial approved for a NHP. WBTI has secured startup funding and a strategic partner, and expects sales revenue in six months.

Seeking: $400K seed financing, industry partnership/licensing opportunity, customer engagement

Contact information:
Dr. Joseph Elliot, CEO | jelliot@windsorbotanical.com
AceAge

www.aceage.com

AceAge builds Bluetooth-connected products to help manage the impact of the aging process. AceAge’s leading product is MedAngel, a medication delivery system that delivers the right meds at the right times to patients in their homes. It leverages packaging technology designed for hospital and managed care, delivering a compliance and adherence solution for patients in their home.

Seeking: $500K seed financing

Contact information:
Spencer Waugh, Co-founder  |  spencer@aceage.com

Alaunus

www.alaunus.com

Alaunus provides a time-efficient, mobile, and patient-centric workflow automation platform to homecare agencies and care providers. Care providers can eliminate up to 15% of their day spent manually managing paperwork and focus on improving patient care with scheduling, charting and collaboration at their fingertips. Agencies and organizations can minimize costs and drive higher billings with better Revenue Cycle Management by automating the end-to-end workflows of patient intake, billing rules, team scheduling, visit verification, and invoicing/payroll in a single platform.

Seeking: $450K seed financing, customer engagement, industry partnership

Contact information:
Andrew Ringer, CEO  |  andrew.ringer@alaunus.com
AprilAge

www.aprilage.com

The human face can tell a powerful story—a story that gets more significant with age. AprilAge was founded with the belief that imagery can compel positive behaviour modification in lifestyle choices to improve our health. More than 450 customers in 30 countries already know how APRIL® Face Aging Software can motivate people to change or avoid risky lifestyle behaviours such as smoking, weight gain, and excess sun exposure that endanger their future health and lead to high treatment costs. Healthcare providers, employers and insurance companies that need the next generation of tools for patient and population health use APRIL® as an effective instigator of lasting human health behaviour change.

Seeking: $3M equity investment, international customer engagement, channel partners

Contact information:
Alexandra Brown, CEO & Co-founder | abrown@aprilage.com

Cogniciti

www.cogniciti.com

A critical task for dealing with the dementia epidemic that has accompanied our aging population is the early detection of brain health problems. Cogniciti and the science team from the world’s leading research centre for memory and aging have developed an online early-warning brain health assessment that will revolutionize brain health research/care by a) saving significant cost/time in the recruitment of research volunteers and b) improving patient outcomes at lower cost through earlier detection/treatment. Market engagement has been exceptional: 34,000 assessments have been completed in response to a single Canadian media release.


Contact information:
Michael Meagher, President | mmeagher@cogniciti.com
Evolution Health Systems

Evolution Health helps pharmaceutical companies uncover barriers to medication adherence and prescribing. We develop forecasting models to identify non-adherent behaviours by patients being treated for specific conditions. We data mine the risk factors for each indication and formulation so we can design solutions that have the highest impact, whether text messaging with live support, brief interventions, or expert-moderated online communities. Outcomes and data analytics demonstrate measurable improvements to the bottom line, and are rooted in our rich history of peer-reviewed publications and ROI-focused modeling.

Seeking: Industry partnership/licensing opportunity, customer engagement

Contact information:
Trevor van Mierlo, CEO  |  tvanmierlo@evolutionhs.com

GeneYouIn

GeneYouIn, a personalized medicine company, has developed a genome analytics and reporting platform called PillCheck™. It interprets a patient’s genetic variants to help clinicians better understand how that patient may tolerate a medication in advance of making the prescription decision. This decision-support platform combines software reporting with a genetic test that uses state-of-the-art technology to identify specific variations in genes responsible for drug absorption and metabolism. The system provides personalized, actionable recommendations for the selection of commonly prescribed medications.

Seeking: $2.5M equity investment, industry partnership/licensing opportunity, customer engagement

Contact information:
Ruslan Dorfman, CEO  |  ruslan@geneyouin.ca
iamsick.ca
www.iamsick.ca

iamsick.ca is an award-winning website and mobile platform that seamlessly connects patients to healthcare services. Our current offerings include comprehensive healthcare system wayfinding, EMR-integrated e-booking, real-time wait-time analytics, virtual queuing, and a virtual waiting room. We address unmet healthcare and business needs of patients, health service providers and healthcare system leaders. Available online, and in Apple, Android and BlackBerry app stores.

Seeking: Angel round investment, industry partnership/licensing opportunity, customer engagement

Contact information:
Ryan Doherty, President & Co-founder  |  rsd@iamsick.ca

Infonaut
www.infonaut.ca

Infonaut is a health informatics and performance management company for infection prevention & control. Our mission is to save lives by reducing hospital-associated infections. We organize and integrate evidence to drive new and effective infection prevention interventions to enable immediate, sustained and persistent improvement. We use big-data and advanced analytics to predict risk and behaviours that improve patient safety. By applying proprietary measures and benchmarks we guide evidence-based interventions for infection reduction. The outcome is reduced infections, improved patient safety and significant ROI.

Seeking: $2M Pre-Series A

Contact information:
Thomas P. Quinn, President and CEO  |  tquinn@infonaut.ca
Koronis
www.medlinx.org

Medlinx is a next-generation clinical collaboration platform, connecting clinicians to each other and their patients. It takes what clinicians are already doing now, through emails, texts, calls, written notes, excel sheets and whiteboards when caring for a patient, and allows them to accomplish this on a single, secure mobile platform, integrated with patient data from existing sources. Medlinx enables clinicians and patients to be more informed and connected, improving workflows and patient engagement and satisfaction.

Seeking: $500K seed round, industry partnership/licensing opportunity

Contact information:
Dr. Ali Esmail, CEO | ali@koronishealth.com

ManagingLife
www.managinglife.com

ManagingLife helps thousands of people with chronic pain better understand their conditions and communicate with their doctors through our smartphone app, Manage My Pain. However, we are more than just another app, as we are leveraging our unique patient-first approach to become the standard for communicating and managing chronic pain. Our vision is to build the world’s largest repository of patient-reported pain information to generate invaluable insights for providers, payers, and pharma.

Seeking: Industry partnership/licensing opportunity, customer engagement

Contact information:
Tahir Janmohamed, CEO & Founder | tahir.janmohamed@managinglife.com
MEMOTEXT Corp
www.memotext.com

Validated in clinical and commercial settings, MEMOTEXT improves the bottom line for healthcare stakeholders by increasing patient adherence and scaling behaviour change. Tailored to a population or brand’s requirements, we personalize digital health outreach using patient data to sustain patient engagement for the long term. Our solutions are evidence-based, condition specific and self-referencing digital interventions for sustained ROI driven adherence increases. MEMOTEXT behaviour change algorithms adapt to the changing biometrics, behaviours and circumstances of each patient.

Seeking: Industry partnership/licensing opportunity, customer engagement

Contact information:
Amos Adler, Founder & President | amos@memotext.com

---

Merge3D
www.merge.net

Merge provides mobile, real-time, non-contact hospital room sensor measurement infrastructure and analytics that continually quantify patient risk to proactively reduce patient harms. The system monitors the room environment, the bed status, the occupant status, infection control compliance and fall risk prevention and detection. The digital data collected allows healthcare workers at the tactical, operational and strategic levels to make decisions based upon risk instead of relying on old data (or no data).

Seeking: Equity investment, industry partnership/licensing opportunity, customer engagement

Contact information:
Scott Leslie, CEO | scott@merge.net
NerveVision

NerveVision™ is a software diagnostic support platform designed for the 3D visualization of nerves. The software is a FDA-cleared, patent-pending program that reconstructs a 3D image of any peripheral nerve taken from a standard MRI series. This allows the clinician to see the actual MRI slice where the nerve abnormality exists. The technology has implications for the diagnostic assessment and therapeutic treatment of nerve disorders and pain management, enabling more accurate and direct interventions in pre-surgical planning.

Seeking: $3M Series B financing, industry partnership/licensing opportunity, customer engagement

Contact information:
Dr. Lionel Lenkinski, CEO  |  lionel@nervevision.com

QoC Health

QoC Health deploys patient engagement solutions to support shifting care to the community. These solutions save money, improve outcomes and improve user experiences. All of these white-labeled solutions run off our adaptable Cloud Connect technology platform, which helps our clients deploy patient engagement programs quickly while minimizing cost and organizational risk.

Seeking: $800K seed round equity investment, industry partnership/licensing opportunity, customer engagement

Contact information:
Raymond Shih, President & Founding Partner  |  raymond.shih@qochealth.com
SeamlessMD

www.seamless.md

SeamlessMD provides a patient engagement platform for guiding patients through surgery. Available on smartphones, tablets and computers, patients are supported through preparation and recovery with timely reminders, interactive care plans and self-management tools. Patient generated data is available to healthcare providers in real-time to monitor patients remotely, improve outcomes and lower costs. The company has been named a Forbes 30 Under 30 in Healthcare and 1 of the Top 20 Hottest Innovation Companies in Canada by CIX.

Seeking: Industry partnership/licensing opportunity, customer engagement

Contact information:
Dr. Joshua Liu, CEO | joshua@seamless.md

Shift Health

www.shifthealth.ca

Shift Health improves outcomes by providing valuable insights into what your patients think, and why they behave the way they do. Moving beyond the Quantified Self of patient-generated data from wearables, Shift Health’s unique data collection capabilities empower organizations to act upon the Qualified Self based on patient-reported data. Our unique approach is language and culturally agnostic. You are better equipped to efficiently engage all of your patients as partners in their care. When patients are partners, you will reduce readmission rates, improve clinical outcomes, lower costs of care, and strengthen the relationship with patients.

Seeking: Industry partnership/licensing opportunity, customer engagement

Contact information:
Daniel Penn, President & Co-founder | daniel@shifthealth.ca
Aegis Medical Innovations

Aegis Medical Innovations has partnered with Mayo Clinic and developed a minimally invasive cardiovascular technology to help prevent strokes in patients with atrial fibrillation (AF). Aegis is currently running a clinical trial to prove out the feasibility of a simpler, cheaper and safer percutaneous procedure for left atrial appendage (LAA) closure. Aegis’ system will provide significant advantages over all existing treatments to the patient, physician and payers. The “low hanging fruit” patients requiring LAA closure represent a $4 billion global market opportunity.

Seeking: Industry partnership/licensing opportunity

Contact information:
Trevor McCaw, President | trevor@aegismedical.net

Colibri Technologies

www.colibritech.com

Colibri’s first product, the Foresight™ imaging system, provides high resolution imaging of the cardiovascular system during procedures such as cardiac ablations and structural heart interventions. Colibri developed the world’s first proprietary 3D, forward-viewing intracardiac echocardiography (ICE) system, scheduled for market entry in 2015. Our product pipeline also includes a catheter and imaging system that combines the two most frequently used intravascular imaging (IVI) modalities into a single device for the $450 million IVI market.

Seeking: $2-5M equity investment

Contact information:
Brian Courtney, CEO | brian@colibritech.com
illumiSonics

illumiSonics Inc. was founded with the vision of producing innovative optical and ultrasonic technologies for medical and industrial applications. We are introducing a novel medical imaging system called photoacoustic remote sensing (PARS) microscopy. PARS is capable of remotely performing absorption-based imaging of microvasculature and blood oxygenation and can be integrated with other optical imaging systems. Target markets will include pre-clinical imaging in academic and pharmaceutical sectors followed by medical sectors with a focus on dermatological and gastroenterological imaging.

Seeking: $5M equity investment, industry partnership/licensing opportunity, customer engagement

Contact information:
Parsin Hajireza, CEO  |  parsin@illumisonics.com

Interface Biologics

Interface Biologics, Inc. (IBI) is a commercial-stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. Our patent-protected technologies include antithrombogenic additives for blood-containing medical devices and polymer enabled combination drug delivery devices. IBI has exclusive Endexo™ technology licensing agreements with AngioDynamics (NASDAQ: ANGO) for vascular access catheters and with Fresenius Medical Care (NYSE: FMS) for chronic dialysis systems. IBI also has a joint venture commercial agreement with Qualimed to develop a drug-coated balloon based on IBI's Kinesyx™ technology.

Seeking: Industry partnership/licensing opportunities

Contact information:
Mark Steedman, Vice President, Business Development  |  msteedman@interfacebiologics.com
Lumasonix

www.lumasonix.com

Lumasonix is a development-stage medical imaging company focused on early detection of breast cancer. Lumasonix proprietary sensor technology enhances the emerging photoacoustic CT that accurately finds malignant cancer tumours in early clinical stages without the need for invasive biopsies. Photoacoustic CT is clinically proven to work for all women including those with small or dense breasts. Lumasonix Breast Imager will generate functional tomograms of cancer tumours like MRI but with the speed and convenience of mammography, without painful breast compressions, risky x-ray radiations or radioactive infusions.

Seeking: $2M seed financing, industry partnering/licensing opportunities, customer engagement

Contact information:
Naveed Nazir, CEO | naveed@lumasonix.com

Medella Health

www.medella.ca

Medella Health is a wearable technology startup out of Waterloo. We are developing contact lenses that continuously and non-invasively monitor glucose levels, and transmit the information to a mobile device, so patients can better manage their diabetes. With our system, not only will patients be able to see their glucose trends over time, but share the information with their clinicians and healthcare providers.

Seeking: Industry partnership

Contact information:
Harry Ghandi, CEO & Co-founder | harry@medella.ca
Mindful Scientific

www.mindfulscientific.com

Mindful Scientific is developing the Halifax Consciousness Scanner (HCS), a portable medical device that rapidly assesses brain function to aid in the diagnosis, monitoring and management of concussion and other neurological problems. The proprietary solution delivers a stimulus rich auditory sequence and passively measures, and internally analyzes resulting brainwaves to provide meaningful results quickly. This critical information can be used for treatment decisions to manage patient care, improve patient outcomes and quality of life, and potentially reduce healthcare costs.

Seeking: $500K seed financing, industry partnership/licensing opportunity, customer engagement

Contact information:
Ying Tam, CEO & President | ying.tam@mindfulscientific.ca

MolecuLight

www.moleculight.com

MolecuLight is an early-stage medical imaging company that focuses on the development and commercialization of optical imaging-based solutions, providing relevant, actionable information at the point-of-care. The first product is intended to allow clinicians to quickly, safely and easily visualize bacterial presence (based on fluorescence imaging) and distribution in skin and chronic wounds in real-time. The platform will also leverage additional products including software and bioassays. MolecuLight's mission is to provide the healthcare industry with world-class products and services.

Seeking: Equity investment, industry partnership/licensing opportunity, customer engagement

Contact information:
Craig Kennedy, CEO | c kennedy@moleculight.com
NP Screen

www.npscreen.com

NP Screen sells a minimally invasive, high-accuracy screening test for the early identification of virally-caused nasal cancer. Cancer can be identified, with the highest accuracy, making required treatments more manageable and affordable to patients. The technology platform is based on the identification of viral infection via DNA assay/PCR. Identification and early detection of cancerous growth ensures better treatment outcomes for patients. The company will commercialize its screening tests in international markets in partnership with other diagnostic companies.

Seeking: $10M Series B equity investment, industry partnership

Contact information:
Leo Chui, Director of Operations | leo.chui@npscreen.com

Perimeter Medical Imaging

www.perimetermed.com

Perimeter takes the guesswork out of tumour removal surgery. Over 25% of breast lumpectomy surgeries require a second surgery due to some cancer cells being left behind. This causes significant stress on patients and their families, and results in added healthcare costs. Perimeter’s OTISTM System is the only solution that provides clinicians with a high resolution image of the entire surface of the removed tumour, providing accurate information in real time, to make better decisions and ultimately reducing the need for follow-up second surgeries.

Seeking: $5-7M Series B equity investment

Contact information:
Paul Weber, CEO & President | pweber@perimetermed.com
Proteocyte Diagnostics

www.proteocyte.com

Proteocyte Diagnostics commercializes Straticyte, the first and only molecular diagnostic test for oral precancerous lesions that provides an objective and accurate prediction score (90% predictive value) as evidenced by retrospective clinical studies. Unlike standard of care based on subjective and less accurate visual assessment methods (50% predictive value), Straticyte provides a reliable assessment of the risk for progression to cancer and helps clinicians save lives, improve quality of life and reduce healthcare costs.

Seeking: $1M Series A financing

Contact information:
Mario Thomas, President | mthomas@proteocyte.com

Rna Diagnostics

www.rnadiagnostics.com

Rna Diagnostics has developed a molecular diagnostic technology that radically improves cancer chemotherapy management. The RNA Disruption Assay™ (RDA™) helps oncologists to rapidly assess effectiveness of chemotherapy. RDA determines whether chemotherapy is working in individual patients after one treatment. Clinical validation for RDA was completed by establishing association of RDA with enhanced disease-free survival in multiple breast cancer trials in North America and Europe. RDA test services are provided to customers from the RDA laboratory in Sudbury, Ontario.

Seeking: $2M Series A financing

Contact information:
John Connolly, Vice President, Corporate Development | jconnolly@rnadiagnostics.com
TrendyMED

www.trendymed.com

TrendyMED has developed the MobileIV™ infusion device, a revolutionary, cost effective product that provides intravenous (IV) infusion in a way which increases mobility, improves safety and enhances quality of life and care. Powered by a unique patented technology, the MobileIV™ does not require any electricity or even batteries and can be mobilized safely and easily anywhere, anytime and in any position at a fraction of what traditional devices cost, offering greater value to both patients and healthcare providers.

Seeking: $3M Series A financing, industry partnership/licensing opportunity, customer engagement

Contact information:
Ronny Barrelli, CEO & Founder  |  ronny@trendymed.com

VieLight

www.vielight.com

Alzheimer’s disease affects 36 million people worldwide. Currently there is no cure. Vielight is a novel technology that uses transcranial and intranasal infrared light to help improve cognition and memory functions based on published research data. The Vielight system is affordable, portable and used for research at Boston University and Harvard University. Relying only on word of mouth, Vielight has sold more than 10,000 general wellness devices worldwide but now requires regulatory clearance and distribution partnership to fulfill its potential.

Seeking: Licensee or partner

Contact information:
Lew Lim, President & CEO  |  lewlim@vielight.com
VitalSines

www.iheartalive.com

VitalSines is developing personal health monitoring technology with a razor sharp focus on consumer need and acceptance. The VitalSines team has world-class expertise in bio-signal acquisition and analysis. Using an optical pulse sensor on a finger, VitalSines is able to continuously monitor blood pressure. Using an optical pulse sensor on the palm, VitalSines is able to provide motion tolerant blood oxygen saturation. Using an armband, VitalSines is able to continuously monitor health and create a new vision of human life.

Seeking: $1M Series A equity investment, industry partnership/licensing opportunity, customer engagement

Contact information:
Jess Goodman, CEO | jess@iheartalive.com
Acknowledgements

Thank you to all the expert health advisors, application reviewers and pitch coaches who have made MaRS HealthKick 2015 such a success. With your hard work and dedication, we were able to open up this year’s competition to more health ventures from across Canada, offering exposure and funding for startups in a sector where capital is difficult to secure and product development is time-consuming and costly. Thank you to Peter Evans, BDC, RBC, Lumira Capital and Norton Rose Fulbright for providing their expertise and assisting the HealthKick finalists with putting the final touches on their pitch presentations. We thank all our speakers, sponsors, supporters, jury members, volunteers and attendees who have made Canada’s largest health venture showcase a possibility.
For more information on HealthKick 2015, please visit:

healthkick.marsdd.com

To follow the conversation on Twitter, use the hashtag:

#HealthKick2015
#HealthKick2015
healthkick.marsdd.com